First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Stock Price Today
Aura AI Summary
Key Stats
- $454.07MMarket Cap
- 72,489Volume
- Sector/ThematicSector
- $68.4752W High
- $41.1052W Low
- 55 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, First Trust NASDAQ Clean Edge Green Energy Idx Fd has traded between a low of $41.1 and a high of $68.47, highlighting its annual price range. Buy and sell First Trust NASDAQ Clean Edge Green Energy Idx Fd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Most Recent News
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.